Biologics Market Size, Share, Growth Analysis, By Product(Microbial, Antisense and RNAi Therapeutics Mammalian, Others), By Disease(Oncology, Hematology Disorders), By Manufacturing(Outsourced, and In-house), By Region - Industry Forecast 2024-2031


Report ID: SQMIG35H2127 | Region: Global | Published Date: July, 2024
Pages: 219 |Tables: 155 |Figures: 78

Biologics Market Insights

Global Biologics Market size was valued at USD 462 Billion in 2022 and is poised to grow from USD 510.05 Billion in 2023 to USD 11125.55 Billion by 2031, at a CAGR of 10.40% during the forecast period (2024-2031). 

The global biologics market has performed well with significant growth and development in recent years. Biologic drugs also known as biologics, they are pharmaceutical compounds derived from living organisms such as humans, animals and microorganisms. These compounds are biologically stable and synthesized by biotechnology, often involving recombinant DNA technology. The biologics market offers innovative and effective therapies for various diseases and medical conditions. Biomedicine has revolutionized treatment, offering targeted and personalized approaches to patients. It is widely used in treating chronic diseases like cancer, immune system and infectious diseases. The market aims to develop and distribute biopharmaceuticals that improve disease control and improve quality of life. The growth factors of the biopharmaceutical market are the increasing prevalence of chronic diseases across the globe. The increasing incidence of diseases such as cancer, diabetes and arthritis has increased the demand for biopharmaceuticals. The importance of preservation and transfer of biomass is sensitive to temperature and environmental factors. Maintaining organic integrity and consistency throughout the supply chain can be complex and expensive.

US Biologics Market is poised to grow at sustainable CAGR for the next forecast year

Market snapshot - 2024-2031

Global Market Size

USD 462 Billion

Largest Segment

Microbial

Fastest Growth

Microbial

Growth Rate

10.40% CAGR

Global Biologics Market ($ Bn)
Country Share for North America Region (%)

To get more reports on the above market click here to Buy The Report

Biologics Market Segmental Analysis

Global Biologics Market is segmented on the Source, Manufacturing and region. By Product, the market is segmented into Antisense and RNAi Therapeutics, Microbial, Mammalian, Others. By Application, the market is segmented into Outsourced, In-house. By Disease, the market is segmented into Oncology, Hematology Disorders.  By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.  

Analysis by Product   

The monoclonal antibodies segment accounted for 66.42% share in 2023 as this drug class was widely used in various therapeutic areas. MAbs can target unhealthy cells without harming healthy cells. So far, monoclonal antibodies have emerged as the main class of approved antibodies. In 2021, the U.S. FDA reached a milestone by approving its 100th monoclonal antibody product. This is due to their lower risk of immune activation compared to chimeric antibodies. 

The antisense and RNAi therapeutics segment is anticipated to expand at a CAGR of 20.6% for the duration of the forecast duration. These biological properties facilitate genes, leading to the development and approval of many gene-silencing drugs for genetic illnesses. For example, In June 2022 Alnylam Pharmaceuticals, Inc. received FDA approval for its RNAi therapy AMVUTTRA for the treatment of Polyneuropathy associated with hereditary transthyretin-mediated amyloidosis. 

Analysis by Disease Category 

The oncology segment dominated the biologics industry with a 28.40% share in 2022. According to the American Cancer Society, about 1.92 million new cancers will be the second leading cause of cancer in the US. in 2022. The advent of biologics, particularly monoclonal antibodies and immunotherapy therapies has dramatically increased cancer treatment by improving survival rates. 

The hematology disorders segment is expected to expand at the fastest CAGR of 11.7% during the forecast period. Approval of gene therapies for rare blood disorders such as the hemophilia is expected to be a key driver for market growth. For example, in November 2022, the U.S. The FDA approved CSL Behring Hemgenix for the treatment of adults with hemophilia B. In addition, in August 2022, BioMarin ROCTAVIAN was also approved in Europe for the treatment of hemophilia A.

Global Biologics Market By Product (%)

To get detailed analysis on other segments, Request For Free Sample Report

Biologics Market Regional Insights

In 2022, North America held the most important sales proportion of 44.37% in the biologics marketplace. This may be attributed to several elements. Additionally, North America is domestic to several leading biopharmaceutical corporations, contributing to the growth of the marketplace. Favorable reimbursement guidelines and sizeable investments in studies and development in addition help the market's expansion. 

The Asia Pacific place is projected to grow at a CAGR of 11.0% during the forecast length. The region is experiencing a growing burden of sicknesses like most cancers, diabetes, and cardiovascular diseases, coupled with a boom in the geriatric population. This has brought about an improved demand for biology in the place. Market leaders inside the industry are actively specializing in assembly this demand and making enormous investments in the development of superior biologic merchandise.

Global Biologics Market By Geography
  • Largest
  • Fastest

To know more about the market opportunities by region and country, click here to
Buy The Complete Report

Biologics Market Dynamics

Biologics Market Drivers

Increased Chronic Diseases 

  • The increasing incidence of chronic conditions such as cancer, diabetes and autoimmune diseases has led to a demand for advanced biological therapies. These therapies use targeted therapy built and effective without conventional chemicals, boosting market growth. 

 Advances in Biotechnology 

  • Technological advances in biotechnology, including genetic engineering, protein expression systems, and monoclonal antibody production, have expanded the capabilities and applicability of biological tools. This innovation increases the development of new natural medicines and helps market expansion. 

Restraints 

High Production Costs  

  • The development and manufacture of natural merchandise calls for complex and costly techniques. These stringent regulatory requirements can restrict the affordability and availability of biologic cures, affecting marketplace boom. 

Regulatory Approval Challenges  

  • Bioscientists face the rigorous regulatory scrutiny and prolonged approval approaches, that can delay new treatments achieving the market. These challenges can hinder the growth of the bioscience sector, especially for emerging and smaller biotechnology companies.

Request Free Customization of this report to help us to meet your business objectives.

Biologics Market Competitive Landscape

The global biologics market is characterized via extreme opposition amongst key market gamers striving to hold their market position and benefit from a competitive side. The marketplace is dominated with the resource of essential pharmaceutical agencies, biotechnology companies, and agreement production agencies (CMOs) specializing in biologic drug improvement and production. Companies which include Biogen, Genentech, and Gilead Sciences are interested in growing modern-day biologics and investing in studies to expand medical understanding and recuperation options. Biogen's more than one sclerosis drug, Tecfidera, and Gilead Sciences' antiviral drug, Remdesivir, have made vast contributions to their market presence.

Biologics Market Top Player’s Company Profiles

  • AbbVie (US)
  • Amgen (US)
  • Novartis (Switzerland)
  • Merck & Co. (US)
  • AstraZeneca (UK)
  • Bristol Myers Squibb (US)
  • Sanofi (France)
  • Eli Lilly and Company (US)
  • Gilead Sciences (US)
  • Biogen (US)
  • Celgene (US)
  • Novo Nordisk (Denmark)
  • Takeda Pharmaceutical Company (Japan)
  • Bayer (Germany)
  • GlaxoSmithKline (UK)
  • Boehringer Ingelheim (Germany)
  • Vertex Pharmaceuticals (US)

Biologics Market Recent Developments

  • In January 2023, Johnson & Johnson announced that it would acquire Momenta Pharmaceuticals for US$6.5 billion. Momenta is a leading developer of biosimilars, and the acquisition will help Johnson & Johnson expand its biosimilars portfolio.
  • In February 2023, AbbVie announced that it would acquire Allergan for US$63 billion. Allergan is a leading developer of biologics, and the acquisition will help AbbVie expand its biologics portfolio.
  • In March 2023, Novartis announced that it would acquire AveXis for US$8.7 billion. AveXis is a leading developer of gene therapies, and the acquisition will help Novartis expand its gene therapy portfolio.

Biologics Key Market Trends

  • Improvements in Generalized Medicine: The trend towards personalized medicine is dramatically changing the biological market. Personalized biological therapies tailored to individual genetics and disease characteristics will provide effective and targeted treatment. This trend is driving innovation in biological sciences and expanding their applications in medicine.

Biologics Market SkyQuest Analysis

SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Co-relates, and Analyses the Data collected by smeans of Primary Exploratory Research backed by robust Secondary Desk research. 

According to SkyQuest analysis, the global biologics market is anticipated to enjoy significant boom during the forecast period from 2024 to 2031. They provide targeted and personalised remedies for various sicknesses, which includes most cancers, autoimmune problems, and uncommon genetic conditions. The marketplace evaluation of the biologics industry entails studying different factors that effect its boom and performance. These factors encompass marketplace size, sales developments, marketplace proportion, and competitive panorama. Market analysis additionally includes assessing the call for and supply dynamics, pricing tendencies, regulatory environment, and technological advancements in the enterprise.

Report Metric Details
Market size value in 2022 USD 462 Billion
Market size value in 2031 USD 11125.55 Billion
Growth Rate 10.40%
Base year 2023
Forecast period 2024-2031
Forecast Unit (Value) USD Billion
Segments covered
  • Product
    • Microbial, Antisense and RNAi Therapeutics Mammalian, Others
  • Disease
    • Oncology, Hematology Disorders
  • Manufacturing
    • Outsourced, and In-house
Regions covered North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA)
Companies covered
  • AbbVie (US)
  • Amgen (US)
  • Novartis (Switzerland)
  • Merck & Co. (US)
  • AstraZeneca (UK)
  • Bristol Myers Squibb (US)
  • Sanofi (France)
  • Eli Lilly and Company (US)
  • Gilead Sciences (US)
  • Biogen (US)
  • Celgene (US)
  • Novo Nordisk (Denmark)
  • Takeda Pharmaceutical Company (Japan)
  • Bayer (Germany)
  • GlaxoSmithKline (UK)
  • Boehringer Ingelheim (Germany)
  • Vertex Pharmaceuticals (US)
Customization scope

Free report customization with purchase. Customization includes:-

  • Segments by type, application, etc
  • Company profile
  • Market dynamics & outlook
  • Region

To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.

Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share

Table Of Content

Executive Summary

Market overview

  • Exhibit: Executive Summary – Chart on Market Overview
  • Exhibit: Executive Summary – Data Table on Market Overview
  • Exhibit: Executive Summary – Chart on Biologics Market Characteristics
  • Exhibit: Executive Summary – Chart on Market by Geography
  • Exhibit: Executive Summary – Chart on Market Segmentation
  • Exhibit: Executive Summary – Chart on Incremental Growth
  • Exhibit: Executive Summary – Data Table on Incremental Growth
  • Exhibit: Executive Summary – Chart on Vendor Market Positioning

Parent Market Analysis

Market overview

Market size

  • Market Dynamics
    • Exhibit: Impact analysis of DROC, 2021
      • Drivers
      • Opportunities
      • Restraints
      • Challenges
  • SWOT Analysis

KEY MARKET INSIGHTS

  • Technology Analysis
    • (Exhibit: Data Table: Name of technology and details)
  • Pricing Analysis
    • (Exhibit: Data Table: Name of technology and pricing details)
  • Supply Chain Analysis
    • (Exhibit: Detailed Supply Chain Presentation)
  • Value Chain Analysis
    • (Exhibit: Detailed Value Chain Presentation)
  • Ecosystem Of the Market
    • Exhibit: Parent Market Ecosystem Market Analysis
    • Exhibit: Market Characteristics of Parent Market
  • IP Analysis
    • (Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
  • Trade Analysis
    • (Exhibit: Data Table: Import and Export data details)
  • Startup Analysis
    • (Exhibit: Data Table: Emerging startups details)
  • Raw Material Analysis
    • (Exhibit: Data Table: Mapping of key raw materials)
  • Innovation Matrix
    • (Exhibit: Positioning Matrix: Mapping of new and existing technologies)
  • Pipeline product Analysis
    • (Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
  • Macroeconomic Indicators

COVID IMPACT

  • Introduction
  • Impact On Economy—scenario Assessment
    • Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
  • Revised Market Size
    • Exhibit: Data Table on Biologics Market size and forecast 2021-2027 ($ million)
  • Impact Of COVID On Key Segments
    • Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
  • COVID Strategies By Company
    • Exhibit: Analysis on key strategies adopted by companies

MARKET DYNAMICS & OUTLOOK

  • Market Dynamics
    • Exhibit: Impact analysis of DROC, 2021
      • Drivers
      • Opportunities
      • Restraints
      • Challenges
  • Regulatory Landscape
    • Exhibit: Data Table on regulation from different region
  • SWOT Analysis
  • Porters Analysis
    • Competitive rivalry
      • Exhibit: Competitive rivalry Impact of key factors, 2021
    • Threat of substitute products
      • Exhibit: Threat of Substitute Products Impact of key factors, 2021
    • Bargaining power of buyers
      • Exhibit: buyers bargaining power Impact of key factors, 2021
    • Threat of new entrants
      • Exhibit: Threat of new entrants Impact of key factors, 2021
    • Bargaining power of suppliers
      • Exhibit: Threat of suppliers bargaining power Impact of key factors, 2021
  • Skyquest special insights on future disruptions
    • Political Impact
    • Economic impact
    • Social Impact
    • Technical Impact
    • Environmental Impact
    • Legal Impact

Market Size by Region

  • Chart on Market share by geography 2021-2027 (%)
  • Data Table on Market share by geography 2021-2027(%)
  • North America
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • USA
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Canada
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Europe
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • Germany
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Spain
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • France
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • UK
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of Europe
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Asia Pacific
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • China
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • India
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Japan
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • South Korea
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of Asia Pacific
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Latin America
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • Brazil
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of South America
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Middle East & Africa (MEA)
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • GCC Countries
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • South Africa
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of MEA
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)

KEY COMPANY PROFILES

  • Competitive Landscape
    • Total number of companies covered
      • Exhibit: companies covered in the report, 2021
    • Top companies market positioning
      • Exhibit: company positioning matrix, 2021
    • Top companies market Share
      • Exhibit: Pie chart analysis on company market share, 2021(%)

Methodology

For the Biologics Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:

1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.

2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Biologics Market.

3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.

4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.

Analyst Support

Customization Options

With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Biologics Market:

Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.

Regional Analysis: Further analysis of the Biologics Market for additional countries.

Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.

Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.

Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.

Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.

Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.

Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.

$5,300
BUY NOW

REQUEST FOR SAMPLE

Want to customize this report?
REQUEST FREE CUSTOMIZATION

FAQs

Global Biologics Market size was valued at USD 462 Billion in 2022 and is poised to grow from USD 510.05 Billion in 2023 to USD 11125.55 Billion by 2031, at a CAGR of 10.40% during the forecast period (2024-2031). 

The global biologics market is characterized via extreme opposition amongst key market gamers striving to hold their market position and benefit from a competitive side. The marketplace is dominated with the resource of essential pharmaceutical agencies, biotechnology companies, and agreement production agencies (CMOs) specializing in biologic drug improvement and production. Companies which include Biogen, Genentech, and Gilead Sciences are interested in growing modern-day biologics and investing in studies to expand medical understanding and recuperation options. Biogen's more than one sclerosis drug, Tecfidera, and Gilead Sciences' antiviral drug, Remdesivir, have made vast contributions to their market presence. 'Roche (Switzerland)', 'Johnson & Johnson (US)', 'AbbVie (US)', 'Amgen (US)', 'Novartis (Switzerland)', 'Pfizer (US)', 'Merck & Co. (US)', 'AstraZeneca (UK)', 'Bristol Myers Squibb (US)', 'Sanofi (France)', 'Eli Lilly and Company (US)', 'Gilead Sciences (US)', 'Biogen (US)', 'Celgene (US)', 'Novo Nordisk (Denmark)', 'Takeda Pharmaceutical Company (Japan)', 'Bayer (Germany)', 'GlaxoSmithKline (UK)', 'Boehringer Ingelheim (Germany)', 'Vertex Pharmaceuticals (US)'

The increasing incidence of chronic conditions such as cancer, diabetes and autoimmune diseases has led to a demand for advanced biological therapies. These therapies use targeted therapy built and effective without conventional chemicals, boosting market growth. 

In 2022, North America held the most important sales proportion of 44.37% in the biologics marketplace. This may be attributed to several elements. Additionally, North America is domestic to several leading biopharmaceutical corporations, contributing to the growth of the marketplace. Favorable reimbursement guidelines and sizeable investments in studies and development in addition help the market's expansion. 

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Biologics Market

Report ID: SQMIG35H2127

sales@skyquestt.com
USA +1 351-333-4748

BUY NOW GET FREE SAMPLE